Author: Ravi Shankar

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken:	21st October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	163,438	282.27	282.25
Ordinary shares	Sales	147,617	282.25	282.25

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	22nd October 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9768034903

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

This information is such that the issuer is obliged to make public pursuant to Chapter 15, Section 8 of the Swedish Securities Market Act (2007:528).

Stockholm, 22 October 2026 – Virtune announces that its index provider MarketVector has implemented changes to the rebalancing schedules of two of Virtune’s index ETPs. The adjustments are designed to streamline and align the rebalancing schedules across Virtune’s index product offering, supporting a more consistent and long-term approach to index management.

The following changes have been implemented:

• Virtune Stablecoin Index ETP: The rebalancing frequency remains quarterly, but the schedule has shifted from March, June, September and December to February, May, August and November.
• Virtune Crypto Altcoin Index ETP: The rebalancing frequency has changed from monthly to quarterly, with rebalancing taking place in February, May, August and November. This approach can allow underlying assets more time to benefit from sustained market trends and price movements between rebalancing periods.

The next rebalancing for both products will take place in November 2026. These adjustments align the products’ rebalancing schedules with Virtune Coinbase 50 Index ETP, creating a more harmonized approach across Virtune’s index product offering.

The changes do not affect the products’ investment objectives or fee structures. No action is required from investors.

For further information regarding the index methodology updates, please refer to MarketVector’s official announcement:

https://www.marketvector.com/insights/index-updates/rule-change-for-viralti-and-stablei

Affected products:

Virtune Crypto Altcoin Index ETP (ISIN: SE0023260716)
Virtune Stablecoin Index ETP (ISIN: SE0026821282)

Press Contact

Christopher Kock, CEO Virtune AB (Publ)
Christopher@virtune.com
+46 70 073 45 64

Virtune with its headquarters in Stockholm is a regulated Swedish digital asset manager and issuer of crypto exchange traded products on regulated European exchanges. With regulatory compliance, strategic collaborations with industry leaders and our proficient team, we empower investors on a global level to access innovative and sophisticated investment products that are aligned with the evolving landscape of the global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

WILMINGTON, Del., Oct. 22, 2026 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a wireless, video and AI technology research and development company, recognized the election of Joseph Levy to the IEEE Standards Association Board of Governors, serving as a voting Member-at-Large for the 2027 – 2028 term.

The IEEE Standards Association (SA) is a consensus-building organization that fosters, develops, and advances global technologies. With contributors from more than 160 countries, IEEE standards help drive the functionality, capabilities, and interoperability of a broad range of products and services through collaboration with global, regional, and national organizations. The Board of Governors is comprised of elected and non-voting members and directs the IEEE SA in establishing policy, providing financial oversight, and managing all IEEE standards-related activities.

“Joseph’s election recognizes a legacy of leadership and consensus-building, from leading important Wi-Fi work to serving on the IEEE SA Standards Board,” said InterDigital CTO Rajesh Pankaj. “Every day, billions of Wi-Fi devices worldwide enable video conferences, students learning online, and consumers connecting new devices at home. Joseph exemplifies InterDigital’s commitment to the research and standards empowering those integral experiences.”

In addition to serving a term on the IEEE SA Board of Governors from 2024 – 2025, Joseph has previously served on the IEEE SA Standards Board and several standards-related IEEE committees.

About InterDigital^®
InterDigital is a global research and development company focused primarily on wireless, video, artificial intelligence (“AI”), and related technologies. We design and develop foundational technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. We license our innovations worldwide to companies providing such products and services, including makers of wireless communications devices, consumer electronics, IoT devices, cars and other motor vehicles, and providers of cloud-based services such as video streaming. As a leader in wireless technology, our engineers have designed and developed a wide range of innovations that are used in wireless products and networks, from the earliest digital cellular systems to 5G and today’s most advanced Wi-Fi technologies. We are also a leader in video processing and video encoding/decoding technology, with a significant AI research effort that intersects with both wireless and video technologies. Founded in 1972, InterDigital is listed on Nasdaq.

InterDigital is a registered trademark of InterDigital, Inc. InterDigital is a registered trademark of InterDigital, Inc.

For more information, visit: www.interdigital.com.
InterDigital Contact:
Roya Stephens
Email: Roya.Stephens@interdigital.com
+1 (202) 349-1714

Alphen aan den Rijn – October 22, 2026 – Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 564 of its own ordinary shares in the period from October 15, 2026, up to and including October 21, 2026, for €0.05 million and at an average share price of €82.81.

These repurchases are part of the share buyback program announced on February 25, 2026, under which we intend to repurchase shares for up to €500 million during 2026.

The cumulative amounts repurchased in the year to date under this program are as follows:

Share Buyback 2026

Period	Cumulative shares repurchased in period	Total consideration (€ million)	Average share price (€)
2026 to date	3,887,522	264.2	67.96

For the period starting August 6, 2026, up to and including December 28, 2026, we have engaged a third party to execute €256 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association.

Shares repurchased are added to and held as treasury shares and will be used for capital reduction purposes through share cancelation.

Further information is available on our website:

• Download the share buyback transactions excel sheet for detailed individual transaction information.
• Weekly reports on the progress of our share repurchases.
• Overview of share buyback programs.

For more information about Wolters Kluwer, please visit: www.wolterskluwer.com.

###

About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2025 annual revenues of €6.1 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,100 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). 

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.

Media	Investors/Analysts
Marnie Kontovraki	Meg Geldens
Director	Vice President
Global Communications	Investor Relations
press@wolterskluwer.com	ir@wolterskluwer.com

Forward-looking Statements and Other Important Legal Information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries.

Attachment

• 20261022 Share Buyback Transactions Oct_15_Oct_21 2026

Vaisala, a global leader in measurement instruments and intelligence, introduces Viewlinc Cloud Suite, a cloud-based environmental monitoring offering designed to help organizations establish professional-quality monitoring from day one and build on the same platform as their requirements evolve. The launch is complemented by Vaisala Care for Viewlinc, a lifecycle services offering available in selected markets.

Life science innovation often begins long before organizations establish large-scale or regulated operations. New therapies, diagnostics and technologies may start in a single laboratory or research environment, yet expectations for environmental control, data integrity and operational reliability are already high. As research progresses and operations expand, organizations face increasing demands for documentation, audit readiness and compliance.

Professional-quality monitoring from the start

Vaisala Viewlinc Cloud Suite is designed to help organizations establish environmental monitoring on a professional foundation.

Organizations can focus on their operations rather than maintaining monitoring infrastructure, while retaining real-time visibility into critical conditions. The cloud-based service eliminates the need for a local application server and reduces the associated IT workload.

The offering includes:

• Viewlinc CS Professional Edition for industrial and commercial environments, including environmental monitoring in healthcare facilities, logistics, museums, archives, and research institutions, and condition monitoring applications for power infrastructure.
• Viewlinc CS GxP Edition for regulated life science environments, including pharmaceuticals, healthcare, and medical device manufacturing.

The GxP Edition adds capabilities for GxP compliance, including continuous validation and GxP documentation, while the Professional Edition supports applications that require reliable monitoring without the same compliance and validation requirements.

Organizations can choose the edition that best fits their operational, monitoring and regulatory requirements, including whether their application operates in a GxP-regulated environment.

From laboratories to regulated operations

Life science innovations depend on trusted data and controlled environmental conditions, making reliable monitoring critical throughout the innovation journey.

“The next breakthrough therapy, diagnostic method or biotechnology innovation may begin in a single laboratory. Research taking place today in laboratories, startups and life science innovation hubs can ultimately lead to breakthroughs that transform healthcare and even save lives,” says Jarno Mitjonen, Manager, Software Products, Vaisala’s Industrial Measurements business.

“Those innovations depend on trusted data, controlled conditions and confidence in the environments where that work takes place. A single undetected equipment failure can put years of research at risk, delay a product launch or compromise valuable materials. Organizations need monitoring that protects critical assets and conditions from the start and continues supporting them as their work evolves.”

Confidence beyond the software

Viewlinc Cloud Suite combines trusted Vaisala measurement technology with a modern cloud-based user experience, bringing measurement instruments, monitoring data, and software together in one monitoring solution.

Alongside Viewlinc Cloud Suite, Vaisala is introducing Vaisala Care for Viewlinc, a new lifecycle services offering designed to support customers throughout the operational life of the monitoring system.

The offering includes two service tiers:

• Vaisala Care, a structured package of essential lifecycle services
• Vaisala Care+, a premium offering with more tailored lifecycle support

Services include expert support, remote training, planned system health checks and extended warranty coverage.

The offering helps customers strengthen user competence, improve audit readiness and maintain confidence in their monitoring systems over time.

Vaisala Care for Viewlinc will initially be available in North America, Europe, the Middle East and Africa by the end of 2026.

Key facts

Viewlinc Cloud Suite

• Cloud-based environmental monitoring
• Professional and GxP Editions
• Real-time monitoring, alarms, reporting, and audit trail
• Scalable from small installations to multi-site deployments
• Secure access from desktop and mobile devices
• Available in markets worldwide, excluding China, in Q4 2026

Vaisala Care for Viewlinc

• Lifecycle services for Viewlinc Cloud Suite
• Support, training, system health checks, and warranty coverage
• Available as Vaisala Care and Vaisala Care+
• Initially available in North America, Europe, the Middle East and Africa in Q4 2026

More information for the media

Miia Lahti
Communications Partner, Industrial Measurements, Vaisala
comms@vaisala.com

Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With over 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange.
www.vaisala.com

Attachment

• Vaisala Viewlinc Cloud Suite

Deployment represents BIO-key’s 7th new customer in the Gulf region in the past 6 months

RIYADH, Saudi Arabia and HOLMDEL, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) — BIO-key International, Inc. (Nasdaq: BKYI), a global provider of Identity and Access Management (IAM) and biometric authentication solutions, today announced that a new Middle East government institution has selected BIO-key to modernize and strengthen access security while simplifying the authentication experience for its workforce through the deployment of its PortalGuard^® enterprise IAM platform and biometric authentication technologies.

A deeply security-conscious organization within a Gulf region national government is utilizing BIO-key’s solution to replace legacy authentication methods with secure, passwordless biometric authentication, reducing the risk of credential compromise while improving operational efficiency. As is often the case in high-level IT security deployments, the customer required that its identity not be disclosed.

The implementation includes BIO-key’s award-winning PortalGuard^® platform, Passkey:YOU™ FIDO2 passwordless authentication, WEB-key biometric authentication engine, and EcoID III enterprise fingerprint scanners to provide a fully integrated Identity-Bound Biometrics (IBB) solution. Together, these technologies provide phishing-resistant authentication by binding digital identity directly to the individual rather than to a device, password, or token which pose far greater risk of compromise.

The solution is being delivered in partnership with VaporVM, a strategic integration partner in the Gulf region. VaporVM provides local implementation, deployment, and ongoing technical services to ensure seamless integration and long-term operational success.

Following the recent addition of a government security agency customer, this deployment demonstrates growing traction in BIO-key’s expansion across the Middle East, where governments and critical infrastructure organizations are accelerating investments in digital identity, Zero Trust security, and passwordless authentication as part of broader digital transformation initiatives.

“Security and operational efficiency were our highest priorities throughout this project, and BIO-key delivered a solution that met the exacting standards required by our organization,” commented a senior technical official at the institution. “The transition to biometric authentication has been seamless for our users, and we now have a level of identity assurance and access control that gives us complete confidence in our security environment.”

“This deployment demonstrates BIO-key’s ability to meet the demanding security requirements of highly security conscious organizations,” said Fadi Al Otaibi, Senior Director at VaporVM. “We believe this project will serve as a strong reference for additional government agencies and enterprise organizations looking to modernize their identity infrastructure with passwordless biometric authentication.”

“We are active in one of the world’s most ambitious markets for digital transformation, cybersecurity, and artificial intelligence,” said Alex Rocha, Managing Director, BIO-key. “Being selected by an institution with such demanding security requirements is an important validation of BIO-key’s technology and our Identity-Bound Biometrics strategy. We are honored by the trust placed in our technology and team and look forward to supporting more organizations across the Gulf region as they strengthen identity security and accelerate their digital transformation initiatives.”

About BIO-key International (www.bio-key.com)
BIO-key International, Inc. (NASDAQ: BKYI) is a global provider of Identity and Access Management (IAM) solutions that secure access for enterprises, government agencies, financial institutions, healthcare organizations, manufacturers, and educational institutions worldwide. Its PortalGuard platform delivers Single Sign-On, adaptive Multi-Factor Authentication, passwordless authentication, Identity-Bound Biometrics, identity lifecycle management, and secure access capabilities that help organizations strengthen security while improving user productivity across cloud, on-premises, and hybrid environments.

BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). Words such as “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes,” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on management’s beliefs, assumptions, and information currently available and are made pursuant to the safe harbor provisions of the Act. These statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. These risks and uncertainties include those described under the caption “Risk Factors” in BIO-key’s Annual Report on Form 10-K for the year ended December 31, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except as required by law, BIO-key undertakes no obligation to update or revise any forward-looking statements.

Engage with BIO-key

Facebook – Corporate:    LinkedIn – Corporate: X – Corporate: X – Investors: StockTwits:	https://www.facebook.com/BIOkeyInternational/ https://www.linkedin.com/company/bio-key-international @BIOkeyIntl @BIO_keyIR BIO_keyIR

Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800

• Submission marks an important milestone towards bringing a new treatment option to patients with DMD in South Korea. 
• Vamorolone has already received South Korean Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation. 
• Targeting regulatory approval in South Korea in 2027 and commercial launch in 2028. 

Tokyo, Japan and Cambridge, UK, 22 October 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has submitted a Marketing Authorization Application (MAA) to the Ministry of Food and Drug Safety (MFDS) in South Korea for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). 

As announced on 2 June 2026, vamorolone has received Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation in South Korea. GIFT is a priority review pathway designed to accelerate the review of innovative medicines targeting life-threatening or serious diseases, including rare diseases, and is expected to help shorten the review timeline and support earlier patient access to vamorolone. The Company is targeting marketing authorization in South Korea in 2027, followed by a commercial launch in 2028. 

In January 2026, Nxera acquired exclusive rights from Santhera Pharmaceuticals Holding (“Santhera”) to develop, manufacture and commercialize vamorolone in Japan, South Korea, Australia and New Zealand. Nxera is leading regulatory approval, commercialization and manufacturing activities in these territories. Vamorolone is a dissociative corticosteroid developed to preserve anti-inflammatory efficacy while reducing the systemic side effects associated with long-term conventional corticosteroid therapy. It is approved and marketed for the treatment of DMD in the US, European Union, UK and China. 

Mr. MinBok Lee, President and Representative Director of Nxera Pharma Korea, commented: ” This submission marks an important milestone towards bringing a new treatment option to patients with DMD and their families in South Korea. Following the ODD and GIFT designations, we are very pleased to have reached this submission milestone as planned. DMD is a serious, progressive disease requiring long-term treatment, and we believe vamorolone has the potential to address an important unmet medical need by offering a differentiated treatment option with a more favorable long-term safety profile. We will continue to explore ways to bring vamorolone to Korean patients sooner, while working closely with the regulatory authorities towards approval.”  

About Duchenne Muscular Dystrophy  

Duchenne muscular dystrophy (DMD) is a rare inherited X-chromosome-linked disease, which almost exclusively affects males. DMD is characterized by inflammation which is present at birth or shortly thereafter. Inflammation leads to fibrosis of muscle and is clinically manifested by progressive muscle degeneration and weakness. Major milestones in the disease are the loss of ambulation, the loss of self-feeding, the start of assisted ventilation, and the development of cardiomyopathy. DMD typically reduces life expectancy to before the fourth decade due to respiratory and/or cardiac failure.  

About vamorolone  

Vamorolone is a dissociative corticosteroid approved for the treatment of Duchenne muscular dystrophy (DMD). It binds selectively to the glucocorticoid receptor and triggers anti-inflammatory activity through inhibition of NF‑κB-mediated gene transcription, while inducing reduced transactivation of other genes [1]. Vamorolone is not a substrate for 11‑β-hydroxysteroid dehydrogenase (11β-HSD) enzymes, which are involved in the local amplification of glucocorticoid activity in tissues and have been implicated in corticosteroid-associated toxicity [2,3]. This pharmacological profile is the basis for its classification as a dissociative corticosteroid, designed to preserve anti-inflammatory efficacy while reducing the systemic effects associated with long-term conventional corticosteroid therapy [1–3].  

In the pivotal Phase 2b VISION-DMD study, vamorolone met its primary endpoint, demonstrating a statistically significant improvement in Time to Stand (TTSTAND) velocity versus placebo at 24 weeks (p = 0.002) [4]. The most commonly reported adverse reactions were cushingoid features, vomiting, weight increase, increased appetite, and irritability; most were mild to moderate in severity [1]. 

Long-term data from up to eight years of vamorolone treatment were presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in March 2026[5,6]. In propensity-matched analyses, vamorolone demonstrated durable efficacy comparable to standard-of-care corticosteroids and a differentiated safety profile: a lower incidence of vertebral fractures versus deflazacort-treated cohorts (8.1% vs 41.9%; p = 0.0082) [5]; maintained normal growth trajectory with a mean height advantage of 12.17 cm versus conventional corticosteroids (p < 0.0001) [5,6], and a lower incidence of cataracts versus deflazacort (p = 0.015), with no observed cases of glaucoma [5]. 

References 

[1] AGAMREE® (vamorolone) Summary of Product Characteristics. European Medicines Agency; authorised 14 December 2023. 

[2] Heier CR, Damsker JM, Yu Q, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. Life Sci Alliance. 2019;2(1): e201800186. 

[3] Reeves EKM, Hoffman EP, Nagaraju K, et al. VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. Bioorg Med Chem. 2013; 21(8): 2241–2249. 

[4] Dang UJ, Damsker JM, Guglieri M, et al. Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy (VISION-DMD). Neurology. 2024;102(5): e208112. 

[5] Guglieri M, et al. Long-term impact of vamorolone on bone health compared to standard of care glucocorticoids in boys with Duchenne muscular dystrophy. Poster 62S, MDA Clinical & Scientific Conference 2026. 

[6] McDonald CM, et al. Comparative analysis of long-term effectiveness of vamorolone versus standard of care glucocorticoid treatment in boys with Duchenne muscular dystrophy. Poster 23S, MDA Clinical & Scientific Conference 2026. 

–END– 

About Nxera Pharma 

Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). 

For more information, please visit www.nxera.life  

LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma 

Enquiries: 

Nxera – Media and Investor Relations 

Shinya Tsuzuki, VP, Head of Investor Relations 

+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life  

MEDiSTRAVA (for International Media) 

Mark Swallow, Frazer Hall, Erica Hollingsworth 

+44 (0)203 928 6900 | Nxera@medistrava.com  

Forward-looking statements 

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Company advances plans for Chicago-area graphene production facility targeting initial capacity of 10 metric tonnes per quarter, alongside encouraging preliminary lubricant testing results

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Argo Graphene Solutions Corp. (CSE: ARGO | OTCQB: ARLSF | FSE: 94Y) (“Argo” or the “Company”) is pleased to provide an update on its plans to establish a commercial-scale graphene refinery in the Chicago, Illinois area, while reporting encouraging preliminary results from its evaluation of graphene as a performance-enhancing additive in industrial lubricants.

Together, these initiatives advance Argo’s strategy to build a vertically integrated graphene business, connecting commercial-scale production with the development of graphene-based products for industrial markets.

Argo’s commercialization strategy is built around its exclusive worldwide licence to Grapherry’s proprietary STREAM™ production technology. The agreement also establishes a contractual pathway to full ownership, supporting Argo’s long-term objective of owning its core production technology.

Advancing Argo’s Graphene Refinery Strategy

Argo continues to advance its plans to establish a commercial-scale graphene refinery in the Chicago area, representing an important step in the Company’s transition from pilot-scale production toward commercial manufacturing.

The Company is in the final stages of securing a facility intended to house its STREAM™ production operations, supporting the manufacture of graphene and graphene oxide for a broad range of industrial applications.

A wholly owned Nevada-incorporated subsidiary of Argo Graphene Solutions Corp. has been granted Authority to Transact Business in Illinois by the Illinois Secretary of State, effective October 15, 2026. The subsidiary is undergoing a corporate name change to better reflect Argo’s expanding portfolio of graphene and graphene oxide products and industrial applications. The Company will announce the new name following regulatory approval.

Argo’s initial development phase targets production capacity of approximately 10 metric tonnes of graphene per quarter, with plans to expand to approximately 90 metric tonnes per quarter as the Company advances its longer-term commercialization strategy.

Argo also plans to expand its graphene oxide production capabilities, initially targeting 30 metric tonnes per quarter of graphene oxide dispersion at a 20% concentration, with further capacity expansion contemplated as commercial operations develop.

The proposed facility is intended to support Argo’s vertically integrated refinery model, combining graphene production with material testing, application development and customer qualification programs.

Following the completion of its C$1.47 million financing in September 2026, Argo intends to advance facility development, production scale-up and customer qualification programs. The planned refinery is expected to support the development of graphene and graphene oxide products for industrial markets, including construction, energy storage, composites, coatings and lubricants, while providing a foundation for future commercial partnerships.

Expanding Industrial Applications: Graphene-Enhanced Lubricants

Alongside its refinery development, Argo is advancing its evaluation of graphene-enhanced industrial lubricants, representing another potential commercial application for its graphene technology.

Preliminary testing has produced encouraging results, demonstrating that graphene remained dispersed in a specially formulated mineral oil for multiple weeks at tested concentrations ranging from 0.05% to 0.50% by weight. Maintaining stable dispersion is an important step toward developing lubricant formulations with the potential to reduce friction, minimize equipment wear and improve operating efficiency. Initial friction testing has also yielded encouraging observations, supporting further performance evaluation and formulation development.

The global lubricants industry represents a substantial market for potential performance-enhancing additives. According to Grand View Research, the global lubricants market is projected to reach approximately US$155 billion in 2026, growing to more than US$204 billion by 2033. Graphene-based additives could potentially enhance existing lubricant formulations across industries including transportation, manufacturing, construction, mining and energy.

Argo intends to continue testing and refining its formulations, with a focus on validating performance improvements and identifying commercially viable applications.

“Our planned Chicago-area refinery is a key step in building the production capabilities needed to commercialize graphene across multiple industrial markets,” said Dr. Vikas Berry, CEO of Argo Graphene Solutions Corp. “The encouraging results from our preliminary lubricant testing highlight another potential application for graphene. Our focus is on advancing production, validating performance and translating these opportunities into commercial products.”

About Argo Graphene Solutions Corp.

Argo Graphene Solutions Corp. is a Canadian advanced materials company developing and commercializing graphene technologies based on the proprietary STREAM™ production platform, exclusively licensed from Grapherry with a pathway to full ownership. Led by CEO Dr. Vikas Berry, Argo is developing a vertically integrated graphene refinery platform designed to connect graphene and graphene oxide production with application development, industrial testing and commercialization.

The Company is evaluating STREAM™ materials across multiple industrial markets, including energy storage, AI infrastructure, semiconductors and advanced electronics, construction, composites, agriculture, coatings and other emerging applications. Argo’s strategy combines advanced-material production, application development, testing, industry collaboration and commercialization.

We seek Safe Harbor.

For further information please contact:
Robert Intile, CFO
Argo Graphene Solutions Corp.
Email: robert.intile@argographene.com
Phone: 604-763-4017
Website: www.argographene.com
Social Media: LinkedIn | Instagram | Facebook | X / Twitter

The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release.

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “will”, “plans”, or variations of such words or phrases. Forward-looking information includes, but is not limited to: statements regarding the transfer of the STREAM™ technology and related intellectual property to the Company; the Company’s anticipated development, manufacture and commercialization of the Stream™ technology and graphene-enhanced products. Forward-looking information is based on assumptions considered reasonable by management as of the date of this news release. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated. Accordingly, readers are cautioned not to place undue reliance on forward-looking information. Forward-looking information speaks only as of the date hereof, and the Company undertakes no obligation to update or revise such information except as required by applicable securities laws.

GRAND CAYMAN, Cayman Islands, Oct. 22, 2026 (GLOBE NEWSWIRE) — Greenlight Capital Re, Ltd. (Nasdaq: GLRE) (“Greenlight Re” or the “Company”) announced today that Greenlight Innovation Syndicate 3456 (“Syndicate 3456”) has appointed Ian Maguire as Active Underwriter, subject to regulatory approval, as Syndicate 3456 transitions from a Syndicate-in-a-Box to a full Lloyd’s syndicate with effect from January 1, 2027.

Syndicate 3456, which writes Greenlight Re Innovations business with a focus on Coverholder partnerships, began underwriting as a Syndicate-in-a-Box on April 1, 2022, with the support of third-party managing agent Asta. The transition to a full syndicate will allow Syndicate 3456 to continue to support innovative Coverholders as well as more traditional Coverholder business, with strong growth anticipated in 2027.

Greg Richardson, Greenlight Re CEO, said:

“Ian has been assisting Syndicate 3456 as a consultant over the last six months, and we are delighted that Ian is now joining Syndicate 3456, as Active Underwriter, at this significant time in the evolution of Syndicate 3456. Ian’s nearly 40 years of experience in the Lloyd’s and London markets, including as Active Underwriter of a major Lloyd’s syndicate with specific expertise in managing delegated authority books of business, will be invaluable as we transition to a full syndicate. While Innovations business will remain the primary focus of Syndicate 3456, we plan to expand our offering to include some more traditional delegated underwriting authority and consortia business, as well as a limited amount of treaty reinsurance. Ian’s appointment highlights the investment we are making in our Lloyd’s platform, which is a key part of our overall strategy.”

Ian Maguire, Active Underwriter, Syndicate 3456 added:

“I am excited to be joining Syndicate 3456 as it transitions to a full syndicate effective January 1, 2027. Having worked with the team in recent months, I have seen first-hand the quality of the underwriting platform and the attractive and diverse portfolio of Innovations business that Syndicate 3456 has developed. Broadening our underwriting appetite is an area where I look forward to applying my experience as Syndicate 3456 grows and establishes itself further in the market.”

About Ian Maguire

Ian Maguire brings nearly 40 years of distinguished Lloyd’s and London market insurance experience. He previously served as Executive Director of Argenta Holdings and, from 2011 to 2021, as Active Underwriter of Argenta Syndicate 2121. During his tenure at Argenta, he managed the syndicate’s property direct and facultative account and oversaw the development of its other, predominantly short-tail, classes of business. Prior to joining Argenta in 2004, Mr. Maguire was responsible for North American direct property facility business at Wellington Underwriting.

About Greenlight Capital Re, Ltd.

Greenlight Re (www.greenlightre.com) provides multiline property and casualty insurance and reinsurance through its licensed and regulated reinsurance entities in the Cayman Islands and Ireland, and its Lloyd’s platform, Greenlight Innovation Syndicate 3456. The Company complements its underwriting activities with a non-traditional investment approach designed to achieve higher rates of return over the long term than reinsurance companies that exclusively employ more traditional investment strategies. The Company’s innovations unit, Greenlight Re Innovations, supports technology innovators in the (re)insurance space by providing investment capital, risk capacity, and access to a broad insurance network.

Forward Looking Statements

This news release contains forward-looking statements concerning Greenlight Capital Re, Ltd. and/or its subsidiaries within the meaning of the U.S. federal securities laws. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the U.S. federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements made on the Company’s behalf. These risks and uncertainties include the impact of general economic conditions and conditions affecting the insurance and reinsurance industry, the timing and outcome of any regulatory approvals, our ability to retain and integrate key personnel, adequacy of our reserves, our ability to assess underwriting risk, trends in rates for property and casualty insurance and reinsurance, competition, investment market fluctuations, trends in insured and paid losses, catastrophes, regulatory and legal uncertainties, and other factors described in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as those factors may be updated from time to time in our periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, which speak only as to the date of this release, whether as a result of new information, future events, or otherwise, except as provided by law.

Investor Relations Contact

Jeremy Hellman
Vice President, The Equity Group Inc.
(212) 836-9626
IR@greenlightre.ky

Serstech has appointed Carl Vilhelm Crona as CCO, effective immediately. Carl has been part of Serstech’s sales team for more than a year and will now assume overall responsibility for the company’s sales organization globally.

Carl brings more than 20 years of experience in International Sales and Sales Management, including 15 years in the Security industry. His extensive professional experience is complemented by academic studies in Business Administration and Communication at Linnaeus University and Malmö University in Sweden.

“Serstech is entering an exciting phase of growth. With his extensive international experience, strong industry expertise and leadership skills, Carl will play a key role in developing our sales strategy and accelerating our growth,” says Stefan Sandor, CEO of Serstech.

For further information, please contact:

Stefan Sandor,

CEO, Serstech AB Phone: +46 739 606 067

Email: ss@serstech.com

or

Arve Nilsson,

Chairman of the Board, Serstech AB Phone: +45 40 35 82 65

Email: arve.nilsson@serstech.com

or visit: www.serstech.com

Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG).

About Serstech

Serstech delivers solutions for chemical identification and has customers around the world, mainly in the safety and security industry. Typical customers are customs, police authorities, security organizations and first responders. The solutions and technology are however not limited to security applications and potentially any industry using chemicals of some kind could be addressed by Serstech’s solution. Serstech’s head office is in Sweden and all production is done in Sweden.

Serstech is traded at Nasdaq First North Growth Market and more information about the company can be found at www.serstech.com